Oral prednisolone + Placebo for oral prednisolone
Phase 3Completed 0 watching 0 views this week📈 Rising
72
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Glycogen Storage Disease Type IA
Conditions
Glycogen Storage Disease Type IA
Trial Timeline
Nov 8, 2021 → Feb 5, 2026
NCT ID
NCT05139316About Oral prednisolone + Placebo for oral prednisolone
Oral prednisolone + Placebo for oral prednisolone is a phase 3 stage product being developed by Ultragenyx Pharmaceutical for Glycogen Storage Disease Type IA. The current trial status is completed. This product is registered under clinical trial identifier NCT05139316. Target conditions include Glycogen Storage Disease Type IA.
Hype Score Breakdown
Clinical
27
Activity
18
Company
5
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05139316 | Phase 3 | Completed |
Competing Products
20 competing products in Glycogen Storage Disease Type IA
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| alglucosidase alfa | Sanofi | Pre-clinical | 22 |
| avalglucosidase alfa | Sanofi | Phase 3 | 76 |
| Myozyme | Sanofi | Phase 2/3 | 64 |
| Myozyme | Sanofi | Pre-clinical | 22 |
| Avalglucosidase Alfa | Sanofi | Phase 2 | 51 |
| Myozyme | Sanofi | Phase 2/3 | 64 |
| ALGLUCOSIDASE ALFA (MYOZYME) | Sanofi | Approved | 84 |
| Avalglucosidase alfa (GZ402666) | Sanofi | Approved | 84 |
| Avalglucosidase alfa (GZ402666) + Alglucosidase alfa (GZ419829) | Sanofi | Phase 3 | 76 |
| Avalglucosidase alfa (GZ402666) + Alglucosidase alfa (GZ419829) | Sanofi | Phase 2 | 51 |
| Alglucosidase alfa | Sanofi | Phase 2 | 51 |
| Avalglucosidase alfa | Sanofi | Approved | 84 |
| Myozyme | Sanofi | Phase 1/2 | 40 |
| Alglucosidase alfa GZ419829 | Sanofi | Pre-clinical | 22 |
| alglucosidase alfa (recombinant human acid alpha-glucosidase [rhGAA]) | Sanofi | Pre-clinical | 22 |
| alglucosidase alfa | Sanofi | Pre-clinical | 22 |
| Cipaglucosidase alfa + Miglustat | Amicus Therapeutics | Phase 3 | 74 |
| BEAM-301: Single dose of BEAM-301 administered by IV | Beam Therapeutics | Phase 1/2 | 36 |
| UX053 + Antipyretic + H2 Blocker + H1 Blocker | Ultragenyx Pharmaceutical | Phase 1/2 | 36 |
| [6,6-2H2]glucose | Ultragenyx Pharmaceutical | Phase 1/2 | 36 |